603739.SHG Qingdao Vland Biotech Co Ltd
- Market cap
- CNY 3.03B
- P/E
- 40.0x
- P/B
- 1.60x
- ROE
- 4.6%
- Dividend yield
- 1.42%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603739.SHG undervalued?
Graham number603739.SHG trades 68.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Qingdao Vland Biotech Co Ltd fundamental analysis
No fundamental analysis for Qingdao Vland Biotech Co Ltd yet.
Qingdao Vland Biotech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Qingdao Vland Biotech Co Ltd
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, food probiotics, environmental microorganisms, and animal and plant probiotics. The company also offers animal vaccines and biological products, such as live and inacti…
Full company profileQingdao Vland Biotech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Qingdao Vland Biotech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 781M | 799M | 814M | 847M | 960M | 1.15B | 1.16B | 1.20B | 1.32B | 1.37B | 1.46B |
| Gross Profit | 426M | 415M | 404M | 410M | 465M | 530M | 500M | 550M | 592M | 612M | 633M |
| Operating Income | 94.7M | 115M | 109M | 97.8M | 142M | 171M | 103M | 123M | 124M | 134M | 151M |
| EBITDA | 153M | 155M | 152M | 137M | 185M | 225M | 175M | 212M | 257M | 258M | 150M |
| Net Income | 82.6M | 85.6M | 83.4M | 77.8M | 109M | 133M | 69.8M | 80.7M | 62.6M | 69.8M | 83.9M |
| EPS | 0.51 | 0.53 | 0.51 | 0.36 | 0.48 | 0.54 | 0.27 | 0.32 | 0.25 | 0.28 | 0.33 |
| Balance Sheet | |||||||||||
| Total Assets | 828M | 884M | 945M | 1.28B | 1.45B | 2.22B | 2.58B | 3.03B | 2.98B | 3.04B | 2.99B |
| Total Liabilities | 270M | 291M | 314M | 249M | 336M | 536M | 845M | 1.21B | 1.11B | 1.13B | 1.05B |
| Shareholders' Equity | 516M | 544M | 570M | 962M | 1.03B | 1.60B | 1.64B | 1.71B | 1.74B | 1.78B | 1.82B |
| Cash & Short-term Investments | 130M | 175M | 160M | 357M | 347M | 482M | 426M | 532M | 448M | 244M | 150M |
| Total Debt | 30.0M | 75.0M | 105M | 36.9M | 67.8M | 236M | 523M | 631M | 596M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 154M | 122M | 85.8M | 65.3M | 173M | 89.5M | 95.3M | 154M | 195M | 114M | - |
| Capital Expenditure | 26.5M | 58.0M | 71.6M | 120M | 212M | 494M | 342M | 216M | 105M | 80.0M | 52.3M |
| Free Cash Flow | 128M | 63.9M | 14.2M | -54.8M | -38.8M | -404M | -247M | -62.1M | 90.7M | 33.9M | 73.3M |
| Ratios | |||||||||||
| ROE | 16.0% | 15.7% | 14.6% | 8.1% | 10.5% | 8.3% | 4.2% | 4.7% | 3.6% | 3.9% | 4.6% |
| ROA | 10.0% | 9.7% | 8.8% | 6.1% | 7.5% | 6.0% | 2.7% | 2.7% | 2.1% | 2.3% | 2.8% |
| Net Profit Margin | 10.6% | 10.7% | 10.2% | 9.2% | 11.3% | 11.5% | 6.0% | 6.7% | 4.7% | 5.1% | 5.7% |
| Debt to Equity | 0.06x | 0.14x | 0.18x | 0.04x | 0.07x | 0.15x | 0.32x | 0.37x | 0.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Qingdao Vland Biotech Co Ltd dividends
- Dividend yield
- 1.42%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 61.6%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 43.0M | 0.17 | 61.6% |
| 2024 | CNY 55.2M | 0.22 | 88.2% |
| 2023 | CNY 39.8M | 0.16 | 49.3% |
| 2022 | CNY 40.3M | 0.16 | 57.7% |
| 2021 | CNY 36.0M | 0.15 | 27.2% |
| 2020 | CNY 30.9M | 0.14 | 28.4% |
| 2019 | CNY 30.9M | 0.14 | 39.8% |
| 2018 | CNY 62.3M | 0.38 | 74.8% |
| 2017 | CNY 60.6M | 0.37 | 70.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 25, 2021.
Who owns Qingdao Vland Biotech Co Ltd
- Insiders 65.74%
- Institutions 3.63%
- Public & others 30.62%
- Shares outstanding 253M
- Free float 85.6M
Qingdao Vland Biotech Co Ltd company profile
- Company name
- Qingdao Vland Biotech Co Ltd
- Ticker
- 603739.SHG
- ISIN
- CNE100003GX8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,522
- Fiscal year end
- December
- Address
- No. 596-1, Jiushui East Road, Qingdao, China, 266100
- Phone
- 86 532 8896 6607
- Website
- vlandgroup.com
About Qingdao Vland Biotech Co Ltd
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, food probiotics, environmental microorganisms, and animal and plant probiotics. The company also offers animal vaccines and biological products, such as live and inactivated, and poultry and swine vaccines, as well as egg yolk antibodies; poultry drugs comprising anti-parastic, antiviral, and nutritional drugs, as well as disinfectants; and traditional Chinese veterinary medicines for scale and avian breeding, livestock, and laying hens. It serves agriculture, animal husbandry, textile, pulp and paper, health care, laundry, biofuel, household cleaning and detergents, food, animal feed, biofuel, environmental protection, washing, and other industries. Qingdao Vland Biotech INC. was founded in 2005 and is headquartered in Qingdao, China.
Qingdao Vland Biotech Co Ltd management
4- Mr. Gang ChenGM & Chairman · born 1975
- Mr. Piyuan QiaoCFO & Director · born 1977
- Mr. Yong JiangBoard Secretary · born 1980
- Hailiang LiAccounting Supervisor